tradingkey.logo
tradingkey.logo
Search

Alexion, AstraZeneca Rare Disease secures pCPA deal for Ultomiris to treat NMOSD and gMG in adults

ReutersAug 7, 2025 12:39 PM

- AstraZeneca PLC AZN.L:

  • ALEXION, ASTRAZENECA RARE DISEASE REACHES AN AGREEMENT WITH THE PAN-CANADIAN PHARMACEUTICAL ALLIANCE (PCPA) FOR ULTOMIRIS FOR THE TREATMENT OF ADULTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) AND ADULTS WITH GENERALIZED MYASTHENIA GRAVIS (GMG)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI